Cas:936074-71-4 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid manufacturer & supplier

Chemical Name:1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid

CAS.NO:936074-71-4

Synonyms:1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid

Molecular Formula:C₁₂H₁₃N₃O₃

Molecular Weight:247.25000

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:79.46000

Exact Mass:247.09600

LogP:1.58880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid Use and application,1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid technical grade,usp/ep/jp grade.

Related News: At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good. 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid manufacturer Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance. 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid supplier You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid vendor Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 1-[1,3]Oxazolo[4,5-b]pyridin-2-ylpiperidine-4-carboxylic acid factory Active pharmaceutical ingredients directly impact disease.